If the enhanced credits currently available to Affordable Care Act (ACA) Marketplace enrollees are allowed to expire for 2026 ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

Some patients dropped out of the trial early because they had lost so much weight.

With a valid prescription, patients can access the starting dose of Zepbound single-dose vial (2.5 mg) for as low as $299 per ...

They’re definitely easier and more affordable than injectables, but do they work as well? Here’s what you need to know.

Eli Lilly is cutting introductory Zepbound prices again, with the lowest dose now $299 monthly for cash-pay customers, a $50 reduction. This move intensifies the price war with Novo Nordisk in the ...

Dec 1 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for U.S.

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S.

With a valid prescription, patients can access the starting dose of Zepbound single-dose vial (2.5 mg) for as low as $299 per month from $349. The 5 mg dose will be available at $399 per month, down ...